B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets

Area of Science:

• Immunology
• Rheumatology
• Pathophysiology

Background:

• Systemic sclerosis (SSc) is an autoimmune connective tissue disease marked by excessive extracellular matrix deposition.
• SSc pathogenesis involves immunological abnormalities, including autoantibody production, with B cells playing a key role.
• The precise link between systemic autoimmunity and SSc clinical manifestations remains unclear.

Purpose of the Study:

• To investigate the role of B cells and CD19 signaling in the pathogenesis of Systemic Sclerosis.
• To explore B cell abnormalities, including CD19 overexpression and hyperreactivity, in SSc.
• To assess the therapeutic potential of targeting B cells in SSc.

Main Methods:

• Analysis of B cell function and CD19 signaling in SSc patients and mouse models.
• Utilizing CD19 transgenic mice and tight-skin mouse models.
• Investigating the effects of bleomycin-induced SSc and CD19 loss in mouse models.

Main Results:

• B cells from SSc patients exhibit upregulated CD19 signaling and overexpression, leading to SSc-specific autoantibody production.
• SSc patients display chronic hyperreactivity of memory B cells, potentially due to CD19 overexpression.
• CD19 loss in mouse models inhibited B cell hyperreactivity, reduced autoantibody production, and improved fibrosis.

Conclusions:

• Altered B cell function, driven by CD19 signaling, contributes to both autoimmunity and tissue fibrosis in Systemic Sclerosis.
• B cells represent a potential therapeutic target for managing SSc.
• Further research is needed to fully elucidate the complex role of B cells in SSc.